MAP1LC3B and cancer: Multiple-variable survival analysis in fact shows that a low expression of glycolytic markers (particularly, HK2, PFKM, and PKM) together with active autophagy–mitophagy (high MAP1LC3B and high BNIP3) predispose AML patients to better prognosis, which could be related to the sensitization of cancer cells to therapy via BECLIN-1-dependent autophagy–mitophagy.